The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Improving outcomes for patients with t(4;14) myeloma: selectively targeting NSD2
Mattia D’Agostino, MD, University of Turin, Turin, Italy, comments on the potential of targeting NSD2 to improve treatment outcomes for patients with multiple myeloma with translocation 4;14 (t:(4;14)). Dr D’Agostino highlights that hypomethylating agents and NSD2 inhibitors, some of which are currently in Phase I clinical trials, may help to improve outcomes for these patients. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As we improve the multiple myeloma treatment, I’m sure that we will improve also the subset of patients. But if you want to selectively target these patients, you have to target NSD2 or the NSD2 effect on the genome. So in one of the talks today, we learned that there are some hypomethylating agents that can help to revert the biology of the cells from these patients, from fourteen positive patients...
As we improve the multiple myeloma treatment, I’m sure that we will improve also the subset of patients. But if you want to selectively target these patients, you have to target NSD2 or the NSD2 effect on the genome. So in one of the talks today, we learned that there are some hypomethylating agents that can help to revert the biology of the cells from these patients, from fourteen positive patients. And there are also nowadays NSD2 inhibitors and some of them are at this moment in clinical trials alone or in combination in Phase I trials. So I think that in the future adding an NSD2 inhibitor to the therapeutic armamentarium that we have available in multiple myeloma would be very important in this subset of patients because it’s specific.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
